Latest Safety News

Anatara Lifesciences reports mixed results from its Phase II GaRP-IBS trial, missing the primary efficacy target but showing significant improvements in anxiety and patient-reported relief, while advancing its anti-obesity pre-clinical program.

Emperor Energy has submitted a key Environmental Plan to NOPSEMA, marking a major step towards drilling the Judith-2 appraisal well in mid-2026 amid tightening east coast gas supply. The company also appointed industry veteran Douglas Jendry as Chairman to steer its next phase.

Peninsula Energy has postponed commissioning of its Lance Uranium Project’s Central Processing Plant to the June quarter, prompting a downward revision of production forecasts through 2027 amid leadership changes and share suspension.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

MC Mining reports steady progress on its Makhado hard coking coal project with key construction milestones met, while Uitkomst Colliery faces production setbacks and rising costs amid depressed coal prices.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet the company progresses its climate transition with key CCS projects and emissions reductions.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% fall in sales revenue, yet the company maintains strong profitability and advances key climate initiatives including the Moomba CCS project.

DGR Global Limited reported steady progress in project generation and strategic investments during Q1 2025, while navigating ongoing legal challenges and securing a $23.5 million funding facility to support operations and refinancing.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.